© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial
June 24, 2024
ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.
After ACS, Long-Term Lipid Management for FH Suboptimal in Women Compared to Men
June 21, 2024
Fiver years after ACS, a new study shows women are less likely to be on lipid lowering therapy and to meet LCL-C target levels than men.
USPSTF Recommends Intensive Behavioral Interventions for Children, Teens with High BMI
June 21, 2024
The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.
George L Bakris, MD, Expert in Hypertension and Metabolic Disease, Has Died
June 20, 2024
Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.
Chronic Hypertension in Pregnancy Increased Two-Fold Between 2008 and 2021
June 20, 2024
The doubling of the diagnosis of chronic hypertension in pregnancy was accompanied by no increase in treatment rates, according to a new study.
Dapagliflozin Approved by FDA to Improve Glycemic Control in Children, Adolescents with T2D
June 19, 2024
Among youth aged 10 to 17 years with uncontrolled hyperglycemia dapagliflozin led to a statistically significant reduction in A1c vs placebo in the T2NOW phase 3 clinical trial.
FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited
June 18, 2024
Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.
Defining Long COVID: Highlights from the National Academy of Sciences Consensus Report
June 17, 2024
In part the National Academies describe long COVID as "a chronic, systemic disease state with profound consequences." The report provides a working definition.
Phase III Trials Show Depemokimab Reduces Severe Asthma Exacerbations with Twice-Yearly Dosing
June 12, 2024
The high potency IL-5 inhibitor can be administered every 6 months, offering a convenient alternative to other biologic agents for appropriate patients with severe asthma.
UPDATE 6-11-2024: Eisai Files sBLA for Lecanemab-irmb Maintenance Dosing
June 11, 2024
The FDA has assigned a PDUFA action date of January 25, 2025 for the monthly IV maintenance dose.